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Methods A systematic search of published evidence was 
performed using Medline (from 1972 to March 2016). 
Review of the relevant literature and recommendations was 
based on authors’ expertise.
Results A review of gender identity and assignment in 
DSD is provided as well as clinical recommendations for 
the management of individuals with DSD.
Conclusions Given the complexity of this management, 
DSD individuals and their families need to be supported by 
a specialized multidisciplinary team, which has been uni-
versally recognized as the best practice for intersexual con-
ditions. In case of juvenile GD in DSD, the prescription of 
gonadotropin-releasing hormone analogues, following the 
World Professional Association for Transgender Health and 
the Endocrine Society guidelines, should be considered. It 
should always be taken into account that every DSD per-
son is unique and has to be treated with individualized 
care. In this perspective, international registries are crucial 
to improve the understanding of these challenging condi-
tions and clinical practice, in providing a better prediction 
of gender identity.
Keywords Disorders of Sex Development · Gender 
Dysphoria · Gender identity · Gender assignment · Gender 
reassignment
Introduction
Sexual differentiation
The normal pattern of human sexual development occurs in 
a highly regulated and dynamic process, dictated by intricate 
genetic activity, and executed by endocrine mediators in the 
form of steroid and peptide hormones [1, 2]. According to 
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the pioneering Jost’s paradigm, the first sexual development 
step is constituted by the establishment of the chromosomal 
sex (i.e., the presence of a Y or X chromosome), at the time 
of fertilization [3]. Then, the chromosomal sex influences 
the determination of the gonadal sex, in differentiating the 
bipotential gonadal ridge into either a testes or an ovary. 
The presence and expression of the testes-determining gene 
SRY, located on the distal part of the short arm of the Y 
chromosome (Yp), determines the gonadal sex of an embryo 
by directing the development of the bipotential embryonic 
gonad into testes, with formation of Sertoli and Leydig cells 
[4]. The differentiation of male testes leads to the secretion 
of specific hormones responsible for translating gonadal sex 
into male internal and external genitalia (sex phenotype) [1]. 
In particular, the anti-mullerian hormone (AMH), produced 
by Sertoli cells, causes the regression of the Mullerian ducts 
and prevents the development of the uterus, fallopian tubes, 
and the distal portion of the vagina [5, 6]. Meanwhile, tes-
tosterone secretion from Leydig cells promotes the Wollfian 
duct differentiation into vasa deferentia, epididymis, and 
seminal vesicles [5, 6]. Testosterone is then converted by 
the tissue-specific isoenzymes, 5-alpha-reductase type 1 and 
type 2, into dihydrotestosterone (DHT), which is responsi-
ble for the masculinization of the external genitalia, includ-
ing phallic enlargement, closure of the urethral folds, and 
development of the prostate and scrotum [7, 8]. Without the 
influence of the sex-determining gene located on the distal 
part of the short arm of the Y chromosome (Yp), the devel-
opment of the embryonic gonad will be driven along the 
female pathway [5, 9]. The Müllerian ducts develop without 
any apparent hormonal input into the uterus, fallopian tubes, 
and the distal portion of the vagina, whereas the Wolffian 
ducts regress and disappear in the absence of androgenic 
stimulation [10]. In addition, the genital tubercle develops 
as a clitoris, the urethral folds form the labia minora, and the 
labioscrotal swellings give rise to the labia majora.
To the aforementioned model, Money et al. [11] added 
the concept of psychosexual development. As demonstrated 
by animal experiments, the process of sexual differentia-
tion is not completed with the formation of genitalia, but 
also the brain, as the substrate of sexual and non-sexual 
behavior, undergoes sexual differentiation consistent with 
the other characteristics of sex [12]. This paradigm sug-
gests that androgens directly (or via the local conversion 
into estradiol) organize the brain in early development, and 
pubertal steroids further activate and reorganize the already 
organized brain, resulting in the expression of masculine 
behaviors [13–19]. The two crucial periods in human devel-
opment when testosterone levels are known to be higher 
in male than in female individuals are mid-pregnancy and 
the first 3 months after birth [20, 21]. These two peaks of 
testosterone, together with functional changes in steroid 
receptors, are thought to fix (and “organize”) the structures 
and circuits in the brain for the rest of a person’s life. The 
rising testosterone levels during puberty activate and reor-
ganize circuits that were built during development [14–16, 
21, 22]. Therefore, psychosexual development is a com-
plex and long-lasting process influenced by multiple fac-
tors, including brain structure, prenatal and postnatal hor-
monal and genetic influences, postnatal environmental and 
psychosocial experiences, and social and familiar circum-
stances [23–25], and is traditionally broken down into three 
domains: gender identity, gender role behavior, and sexual 
orientation [26, 27]. Gender identity refers to a fundamen-
tal sense of belonging and self-identification to one gender 
and to the extent to which a person experiences being like 
others of one’s gender: male, female, or an alternative gen-
der [28]. The term gender role describes the behaviors, atti-
tudes, and personality traits that a society, in a given culture 
and historical period, designates as masculine or feminine, 
that is, more “appropriate” for, or typical of, the male or 
female social role [28]. Sexual orientation is defined by a 
person’s responsiveness to sexual stimuli. The most salient 
dimension of sexual orientation is the sex of the person to 
whom one is sexually attracted. This stimulus class is how 
one defines a person’s sexual orientation as heterosexual, 
bisexual, or homosexual [28]. Therefore, human sexual dif-
ferentiation is a multistep, sequential, interrelated process in 
which genetic information is translated into the phenotype 
of a person who subsequently establishes a male or female 
identity and an awareness of sexual orientation [29–32].
On the basis of phenotypic sex, at birth, the legal gender 
is assigned, with the expectation that the social environment 
will support the formation of a corresponding social gender 
role for the child and that child will later develop gender-
related behavior and a gender identity accordingly [33].
Any hindrance occurring during this complex process of 
sexual differentiation could lead to a misalignment between 
chromosomal, gonadal, and phenotypic sex, classically 
defined as Disorders of Sex Development (DSD) [34]. As 
brain sexual dimorphic differentiation is an integrating 
part of sexual differentiation, it should be considered that 
also the three components of psychosexual development—
gender identity, gender role, and sexual orientation—may 
not always be concordant and aligned in individuals with 
DSD [35]. In fact, as sexual differentiation of the genitals 
takes places much earlier in development (i.e., in the first 
2 months of pregnancy) than sexual differentiation of the 
brain (the second half of pregnancy), these two processes 
may be influenced independently. This means that in the 
event of ambiguous genitals at birth, the degree of mascu-
linization of the genitals may not always reflect the degree 
of masculinization of the brain [36].
Interestingly, recent studies suggest that Gender Dyspho-
ria (GD) could hypothetically be considered as a DSD lim-
ited to the central nervous system, without the involvement 
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of the reproductive tract [25, 33]. GD, according to DSM-5 
criteria, is a condition characterized by a marked incongru-
ence between one’s experienced/expressed gender and the 
assigned one, associated with clinically significant distress 
or impairment in social, occupational, or other important 
areas of functioning [37]. The assumption that GD could be 
considered a DSD is based on the demonstration in male-
to-female (MtF) and female-to-male (FtM) transsexuals of 
a sex reversal in terms of volume and cell number of sex-
dimorphic brain nuclei, such as the central portion of the 
bed nucleus of the striaterminalis (BNSTc) [38–40], the 
gray matter in the right putamen [41], and the interstitial 
nuclei 3 and 4 of the anterior hypothalamus (INHAH3 and 
INAH4) [42]. These findings have been further enhanced by 
the demonstration of gender-atypical brain activation pat-
terns in processing steroid-based odors and erotic stimuli 
[43, 44]. In addition, a recent study found that FtM GD indi-
viduals show stronger more female-typical otoacustic emis-
sions compared to control boys, suggesting that boys with 
GD might have been exposed to relatively lower amounts 
of androgens during early development [45]. In line with 
these studies, it has also been reported that MtF individu-
als have female-typical facial preferences in terms of sexual 
attraction [46]. It has also been postulated that there may 
be genetically based systemic sex hormone abnormalities 
that do no cause abnormalities of the reproductive anatomy, 
but nevertheless influence brain and behavior [33]. Some 
authors, for example, reported an increased number of trinu-
cleotide CAG repeats in the androgen receptor gene in MtF 
transsexuals (generally linked to impairment of androgen 
action) [47]; an increased prevalence of CYP17 gene poly-
morphisms in FtM transsexualism [48], and of significant 
combined partial effects of three polymorphisms in MtF 
transsexualism (CAG repeats in the AR gene, CA repeats in 
the estrogen receptor beta-gene, and tetranucleotide repeats 
in the aromatase gene) [49].
Therefore, in a wider and more current perspective, DSD 
could be defined as all the conditions in which the chromo-
somal, gonadal, phenotypical or psychological (or rather 
gender identity) sex are incongruent [50].
Moreover, the overlap existing between DSD and GD is 
linked to the possibility in both conditions of discomfort or 
distress caused by a discrepancy between gender identity 
and gender assigned at birth [51, 52]. Furthermore, in both 
groups, such distress could lead to a possible gender reas-
signment request. In fact, in non-intersex persons, gender 
identity issues develop, even though all biological sex indi-
cators are differentiated uniformly in the direction of one 
sex or of the other [53]. These indicators include sex chro-
mosomes, sex-determining genes, the gonads, the systemic 
sex hormone milieu during fetal development, puberty, and 
adulthood, and the secondary sex characteristics [53]. Con-
versely, in intersex conditions, the misalignment concerns 
also the biological sex indicators. This concept has been 
emphasized in DSM-5 in which GD diagnosis includes 
both conditions, with and without DSD [37].
Finally, a theoretical relationship between GD subse-
quent to DSD and sexual orientation may be of interest. In 
fact, both gender identity and sexual orientation seem to be 
determined during early development, under the influence 
of a genetic background and factors involved in the interac-
tions between sex hormones and the developing brain [35, 
40]. However, it should be considered that, while GD in 
individuals with DSD may have an impact on the gender 
assignment and reassignment choice, this is not the case 
for sexual orientation. In fact, the distress and/or suffering 
related to a non-heterosexual orientation seems to be more 
the consequence of internalized homonegativity, defined as 
the negative attitudes toward homosexuality by gay and les-
bian persons who reflect negative social beliefs [54].
Therefore, sexual orientation as well as gender-atypical 
behavior do not affect the decision-making process in DSD 
gender assignment. This may explain the fact that studies 
addressing systematically the relationship between gender-
atypical behavior and sexual orientation in DSD are missing.
Genetic aspects involved in DSD
In case of DSD, a molecular diagnosis is made in only 
around 20 % of cases (excluding those due to a steroido-
genic block [55]). Several new genes have been identified 
associated with human errors of primary sex determina-
tion [56, 57]. Approximately 15 % of 46,XY gonadal dys-
genesis carries mutations in SRY, the majority of which 
localized within the HMG domain [56, 57]. Beyond SRY, 
additional sex-determining genes and transcriptional fac-
tors, such as SOX9, NR5A1, GATA4, DAX1, and DHH, 
induce a further maturation of the testes [56]. SOX9 plays 
an essential role in both the specification and differentia-
tion of mesenchymal cells toward the chondrogenic line-
age, as well as establishing Sertoli cell identity in the devel-
oping testis immediately following the expression of SRY 
[56]. Accordingly, recent studies have focused on SOX9 
potential regulatory role in DSD development. Mutations 
involving NR5A1 are associated in humans to a wide range 
of genital anomalies, including gonadal dysgenesis with 
a male-to-female sex reversal, and adrenal insufficiency 
[58]. GATA4, interacting with several proteins, such as 
NR5A1, regulates the expression of genes crucial for testis 
determination and differentiation [58]. Accordingly, differ-
ent mutation in GATA4 has been reported associated with 
errors of testis determination [56]. A role of Desert Hedge-
hod (DHH) in establishing the fetal Leydig cell lineage is 
supported by the gonadal dysgenesis observed in patients 
carrying homozygous mutations, possible due an impair-
ment of Sertoli cell–Leydig cell interaction [56].
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Regarding female sexual differentiation, different sign-
aling molecules have been shown to be necessary for nor-
mal ovarian development, such as R-spondin 1 (RSPO1) 
and WNT4 [59, 60]. RSPO1 mutations have been reported 
in syndromic cases of XX testicular DSD, while mutations 
of WNT4 are associated with various degrees of virilization 
(including androgen excess and abnormal development of 
Mullerian ducts) in 46,XX women.
Aims
The aims of the present review were as follows:
1. to update the main psychological and medical issues 
that surround DSD, in particular regarding gender 
identity and gender assignment;
2. to report specific clinical recommendations according 
to the different diagnoses, when possible.
Methods
A systematic search of published evidence was performed 
including the following words (“sex development” [All 
fields] OR “intersex” [All fields] OR “ambiguous genita-
lia” [All fields]) AND “gender identity” [MeSH] AND 
(“humans” [MeSH Terms] AND English [lang]). The 
search accrued data from January 1, 1955 (the year that 
John Money published his well-known paper on hermaph-
roditism, currently referred to as DSD [11]) up to March 
2016. Studies focusing on GD without DSD, genetics 
aspects of DSD, and sexual satisfaction were not consid-
ered for this review. The identification of relevant stud-
ies was performed independently by three of the authors 
(A.D.F., M.M., J. R.), and conflicts resolved by the third 
investigator (G.F.).
Gender assignment in DSD
One of the most difficult issues in a child with DSD diag-
nosis, particularly in case of ambiguous genitalia, is the 
assignment to the more appropriate gender, and, from a 
parent’s perspective, the gender of rearing [61, 62]. Accord-
ing to many authors, the primary goal in DSD was for gen-
der identity to be consistent with the gender assigned and 
to avoid a gender assignment that would increase the risk 
of GD [25, 35]. In fact, although there is no clear manifes-
tation of GD, it has been reported that both individuals with 
46,XX (27.3 %) and 46,XY (45.5 %) may show a discom-
fort with their gender identity [63]. For many years, accord-
ing to the “optimal gender policy” developed by Money 
[11, 64], it was believed that gender identity should have 
been concordant with assigned sex, assuring that the child 
is raised unambiguously and that appropriate surgical “cor-
rections” and hormone therapies are instituted in line with 
the gender chosen. This assumption was based on the belief 
of the neutrality of gender identity at birth, which devel-
ops its characterization on the basis of postnatal social and 
environment influences [64]. Based on this policy, Money 
suggested assigning a gender to a child with DSD as soon 
as possible and to adjust his/her genitalia surgically in early 
childhood. Then, in his opinion, the gender of rearing will 
later influence the gender identity and gender role of the 
patient. In this perspective, recommendations for gender 
assignment of children with ambiguous genitalia have been 
historically guided by the phenotypic appearance of the 
genitalia, on the basis of which sex would offer the child 
the best opportunity for success particularly in aestheti-
cal, fertility, and sexual terms. Accordingly, most surgeons 
have recommended early surgery, in order to “normalize” 
the genitalia [62]. For example, a 46,XY subject judged as 
having an inadequate penis was assigned female, whereas 
a virilized 46,XX patient with ovaries and a uterus was 
assigned female, independently of the degree of external 
genitalia virilization [35]. In addition, parents were coun-
seled to not disclose the intersex state of the child and often 
shrouded these conditions in great secrecy [61].
This theory, assuming psychosexual neutrality at birth, 
has been challenged in the past decade by refocusing on 
the potential importance of prenatal (e.g., endocrine) and 
genetic influences on psychosexual development [5, 18]. In 
addition, the recent criticism for the management of DSD 
in the past is the result of adults who experienced inter-
ventions too early and have reported GD and uneasiness 
related to the gender assigned. Moreover, many other indi-
viduals report their previous management as an abuse of 
their human rights [65].
Theoretically, assignment should be made as quickly as 
a thorough diagnostic evaluation permits. Because DSD is 
an uncommon phenomenon, there has been limited data 
concerning the eventual outcomes regarding gender iden-
tity, gender role identification, or sexual orientation, and 
in many of these conditions, information about long-term 
gender development is unfortunately not syndrome-spe-
cific [66–71]. The effect of hormonal imprinting on gender 
development may be elucidated through existing animal 
models and also the observations of human case studies in 
DSD patients [61]. Influencing factors include diagnosis, 
genital appearance, therapeutic options, sexual and fertil-
ity potential, cultural practices and pressures, and parental 
view. Individual DSD outcome data regarding gender iden-
tity, quality of life (QoL), avoidance of unnecessary sur-
gery, hormone replacement, and fertility preservation must 
be considered in deciding gender assignment [72–74]. 
Sexual potential, one the most difficult aspect to predict, 
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is also a key factor to be considered for male or female 
assignment [75]. Particularly, penis length and its potential 
to develop during puberty into a sexually functional penis 
are crucial aspects to take into account if male assignment 
is considered. The majority of patients with 5-alpha-reduc-
tase-2 deficiency with a male assignment report satisfac-
tory sexual function as long as they present an adult penis 
length at least 6 cm [76]. Despite the majority of individu-
als with 5-alpha-reductase-2 deficiency present a male 
gender identity, it should be considered that those assigned 
female have been reported with satisfactory sexual activity 
[77]. Among patients with partial androgen insensitivity 
syndrome (PAIS), male gender assignment should be con-
sidered when there is a satisfactory response to testoster-
one therapy in terms of phallic growth, as well as an estab-
lished causative genetic variant [75]. A female assignment 
is suggested if testosterone treatment is without effects 
[75]. Regarding persons with 17-beta-hydroxysteroid 
dehydrogenase type 3 (17-beta-HSD-3) deficiency, sexual 
dissatisfaction has been reported in both male and female 
gender assignments [75].
Available studies suggest that, in women with congeni-
tal adrenal hyperplasia (CAH), interpersonal dynamics and 
the individual’s abilities to cope with different sexual and 
relational situations have more impact in sexual satisfaction 
than genital anatomy [75, 78].
Also fertility potentials should be considered in the deci-
sion-making process for gender assignment, particularly 
before performing an early gonadectomy. For example, in 
5-alpha-reductase-2 and in PAIS patients, sperm retrieval 
and ICSI may be considered [75, 79].
In summary, if a specific diagnosis can be made, recom-
mendations for gender assignment can be based upon out-
come data, when available for the specific DSD diagnosed, 
which are more specifically addressed below in Table 1 
[61, 80]. The Chicago Consensus statement did not include 
specific diagnoses, but some consensus participants have 
provided more specific recommendations described here 
[80]. However, long-term outcomes are needed to establish 
standardized practice guidelines for decision making [81]. 
Moreover, timing of genital surgery should be also taken 
into account. Families should be always made aware of and 
counseled about the pros and cons of early and late assign-
ment [62]. In addition, even when recommendations for 
gender assignment are clear, arguments exist on whether 
surgery can be delayed until the individual can participate 
in the decision and provide consent [62]. In line, some 
countries, as Germany, have recently introduced the possi-
bility to legally choose “male,” “female,” or “x” in the pub-
lic register to ease the pressure of an early assignment for 
newborns DSD.
In any case, it should be taken into account that 
every DSD subject is unique and has to be treated with 
individualized care, preferably with a multidisciplinary 
approach [2, 82, 83] always in the best interest of the child.
Gender reassignment
It should be considered that a small minority of DSDs 
feels the need to change gender later in life, and there-
fore, the assigned gender should not be considered 
immutable [84]. However, it is usually recommended for 
gender reassignment to be always initiated by the patient 
and must be approached very cautiously [72]. Because 
childhood gender dissatisfaction may remit, young indi-
viduals have to be carefully evaluated by skilled special-
ists in order to identify the multifaceted determinants of 
gender identity, as well as biological and social factors 
(i.e., family functioning and support) [72, 85]. In fact, it 
should be considered that, in a considerable percentage 
of individuals, childhood GD does not persist throughout 
adulthood, possibly because in the development phase 
gender identity is still fluctuating [86–88]. Furthermore, 
addressing a possible comorbid psychiatric disorder is 
also essential for better hormonal treatment compliance 
and for building a stable gender identity [66]. Finally, 
sexual and fertility potentials need to be addressed with 
the patient. A similar exhaustive psychosocial and medi-
cal assessment can guide team decisions about gen-
der reassignment, timing of surgery, and sex hormone 
replacement [72]. In particular—when gonads are still 
present and possibly functioning—if eligibility criteria 
are fulfilled (see Table 2) [51, 89, 90], puberty may be 
Table 1  Recommendations for gender assignment by DSD diagnosis 
(Houk and Lee [35], Yang et al. [61] modified)
DSD disorders of sex development
Diagnosis Recommended sex assignment
46,XX DSD
 CAH Female
46,XY DSD
 5-alpha-reductase-2 deficiency Male or female
 17-beta hydroxydehydrogenasi 3 
deficiency
Male or female
 Complete gonadal dysgenesis Female
 Complete androgen insensitivity 
syndrome
Female
 Partial androgen insensitivity Male or female
 Androgen biosynthetic defects Male or female
 Incomplete gonadal dysgenesis Male or female
 Micropenis Male
 Cloacal exstrophy Male or female
 Hypospadias Male
Ovotesticular DSD Male or female
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temporary suspended by using gonadotropin-releasing 
hormone analogues (GnRHa). This treatment leads to a 
gradual regression of sex characteristic development, aid-
ing in prolonging the diagnostic phase, whereas the body 
remains in a neutral early pubertal state. Such option 
could allow both the adolescent and the clinician to 
achieve greater gender clarity and awareness [91]. This 
option may be particularly relevant in case of GD in DSD 
conditions where no clear gender identity outcome can 
be predicted (see Table 1). In line with the Standards of 
Care of the World Professional Association for Transgen-
der Health [89], it is recommended starting GnRHa when 
adolescents have experienced puberty to at least Tanner 
stage 2, because of the important diagnostic value of the 
negative emotional effects related to the first pubertal 
changes [51, 89, 90]. In particular conditions (such as in 
case of a gender assignment at birth different from the 
recommended one), an earlier treatment with GnRHa 
may be also considered. This could be, for example, the 
case of a late diagnosis of a 46,XY DSD in which a male 
assignment is usually recommended (such as 5-alpha-
reductase-2 deficiency). In such condition, if a female 
assignment at birth is performed and no GD is experi-
enced thereafter (because of a female gender identity), 
a puberty suppression could be considered, avoiding the 
(male) puberty progression. The latter, in fact, could be 
perceived by the adolescent as a natural disaster, dev-
astating his/her body and (gendered) integrity [92]. We 
have also to consider that in that case, differently from 
GD without DSD, puberty is characterized by physical 
modifications, possibly inducing a switch in the pheno-
typic sex. ‬ ‬
In case of GD persistence and if eligibility criteria are 
met (see Table 2), puberty induction in accordance with 
the adolescent gender identity should be considered [51, 
89, 90].
MHP role with patients with DSD
The issues that surround DSDs are multidimensional 
and require both an individualized and multidisciplinary 
approach to provide effective diagnosis, treatment, and sup-
port [55, 80]. The ultimate aim of treatment and care for 
patients with DSD are the physical, psychological, and 
sexual well-being within a “patient-centered” view and a 
continuous teamwork [93]. Considering the difference in 
physical appearance and the variation in developmental 
history, the basic processes of successful social and emo-
tional development, as well as self-concept, may be more 
challenging for children and adolescents with DSD than for 
their peers [94]. Therefore, MHPs may play an important 
role in the different phases of the management of DSD. 
Children born with DSD and their families may have dif-
ferent needs, and therefore, the connection with MHPs as 
early as possible may ensure that proper help can be avail-
able when and if psychological needs do arise. Regarding 
the diagnostic phase, MHPs play a role in the assessment 
and management of various mental health needs of the 
child and the family. For example, a psychologist could 
provide support and assist families who may be having 
difficulty coping with the diagnosis of genital ambiguity 
in their child [95] or with the uncertainty about psychoso-
cial and psychosexual outcomes of the child development. 
This implies that parents should be supported in the heavy 
responsibility perceived in decision making, as for example 
gender assignment, options, and timing for early medical 
and surgical interventions [96]. In some cases, identify-
ing and clinically managing DSDs can begin even before a 
child is born; such moments can be perceived as extremely 
stressful as these can often lead to irreversible (and irre-
mediable) outcomes in terms of QoL, psychological and 
medical well-being, and sexual function and satisfaction. 
Therefore, MHPs should always provide information about 
Table 2  Eligibility criteria for GnRHa and cross-sex hormone treatment
GnRHa gonadotropin-releasing hormone analogues, GD gender dysphoria
Adolescents are eligible for GnRHa treatment if they
1. Meet the DSM-5 criteria for GD
2. Have experienced puberty at least up to Tanner stage 2
3. Have an increase in GD at the arrival of (early) pubertal changes
4. Do not suffer from psychiatric comorbidities that interfere with the diagnostic work-up or treatment
5. Have adequate psychological and social support during treatment, and
6. Demonstrate knowledge and understanding of the expected outcomes, risks and benefits of therapy
7. The parents consent to the treatment and give adequate psychological and social support during treatment
Adolescents are eligible for cross-sex hormone treatment if they
1. Meet the criteria for GnRHa analogues
2. Are 16 yrs or older
3. The parents consent to the treatment and give adequate support during
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the pros and cons of any elective interventions [96, 97] and 
inform about the results of medical examinations and about 
the available knowledge on gender development in simi-
lar situations [96]. Also, MHP may evaluate the parents or 
care givers in terms of their education, cognitive capacity, 
coping skills, as relevant to their ability to understand the 
DSD and to nurture a child with a DSD [93]. Possibly, the 
responsibility for treatment decision and adherence to med-
ical treatment can shift to the child, when mature enough 
to become personally engaged in his/her care. Also assess-
ment of parent/child relationship and facilitation of healthy 
parent/child relationship should always be performed 
and investigated [93]. Parents may need help in practical 
aspects related to the DSD management, as the balance 
between secrecy and sharing the medical conditions in the 
social context (who should be told, how and when should 
the information been given) [50]. In fact, the experience of 
DSD could be stigmatizing for the parents leading them to 
avoid family, friends, and social support. Moreover, paren-
tal emotional support should be offered for the possible 
responsibility and guilty feelings that parents may experi-
ence about their child with a DSD.
Studies on the psychiatric characteristics of children 
with DSD are scarce [82]. If psychiatric comorbidity is pre-
sent, it is important to treat the patients with any diagnosis 
of a psychiatric disorder for better treatment compliance; 
furthermore, being without severe psychiatric complaints is 
also essential for building a stable gender identity [82]. In 
this regard, it has been reported that gender dissatisfaction 
(unhappiness with assigned sex) is more frequent in indi-
viduals with DSD than in the general population [82]. Also 
the child’s cognitive functioning should be defined in order 
to assess the child’s ability to participate in the decision-
making process, to explore options. Active participation of 
the child underlines the autonomy and personhood of the 
patient [93], improving self-efficacy and self-esteem.
Puberty can be a challenging period, and some adoles-
cents with DSD may develop anxieties. For example, they 
may postpone initiating intimate relationships because of 
insecurities and fear of rejection [96]. During adolescence, 
while sexual maturation occurs, it is important to promote 
a healthy self-image, as well as addressing sexuality and 
fertility issues within an age-appropriate education. Sexual 
problems indeed occur more often in DSD than non-DSD 
groups [72, 87, 88, 97]. In some cases, MHPs may work 
on the patient’s feelings regarding sexual orientation, if 
issues of internalized homonegativity or struggles with 
dealing with stigma arise. In adolescence, questions may 
emerge or re-emerge about gender identity, gender reas-
signment, and surgical intervention (e.g., some may need 
to know why they have to dilate the vagina or have to make 
decisions about genital surgery) [96]. The sharing of more 
detailed information with the child is an imperative during 
this stage [96].
MHPs, together with the family, play also a role in the 
disclosure of medical and surgical history that should occur 
in an age-appropriate manner and according to the develop-
mental level of the child [97].
Peer support represents another useful form of care for 
patient with and their family, in both formal (in a clinical 
setting, e.g., support groups) and informal (through per-
sonal connections, e.g., Internet groups) settings. In fact, 
meeting others who share the similar challenges has been 
consistently identified by adults and families affected by 
DSD as one of the most therapeutic experiences [50].
Finally, MHPs play an important role in facilitating the 
group process within the team and between the team and 
the family [96].
QoL of patients affected by DSD and their parents
One of the main aims of care for patients with DSD 
should be a good QoL that may be defined by a feeling 
of general health and well-being, being able to work, to 
have an active social life, and to form long-lasting, close 
relationships [98]. DSDs include different conditions that 
are characterized by some common aspects, but also by 
specific difficulties in each diagnostic group and at cer-
tain times: for example, at the initial diagnosis, during the 
developmental stage, at symptom control, during fertil-
ity treatment, or at the beginning and end of an impor-
tant relationship [75]. Therefore, people with DSD may 
be affected at different levels in their QoL areas during 
lifetime. Currently, studies on long-term QoL are scarce 
[98]. In general, follow-up studies have indicated dissat-
isfaction with overall sex life and sexual function [3–5, 
98], as well as with binary gender [99], negative body 
image [100], social isolation [101], and experiencing nor-
malizing surgery as dilemmatic [102]. Also, children are 
described by decreased health-related QoL, whereas par-
ents by lower levels of emotional well-being and lower 
QoL mental health scores than among community sam-
ples [103]. In line with the psychological aspects related 
to DSD described previously, early and constant contact 
with a MHP should be available for children/adolescent 
with DSD and their families in order to have a good QoL 
by promoting competence and experienced efficacy in 
both parents and children with DSD.
Hormone replacement therapy
Hormonal treatment is influenced by the specific DSD 
involved and by social factors, such as gender of rearing 
and gender identity [91].
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DSD with male gender assignment and identity
In infants born with micropenis, 25 mg intramuscular (IM) 
testosterone enanthate every month for 3 months is recom-
mended to induce penile growth. In children with micro-
penis at preschool age, a further short course of 25–50 mg 
IM testosterone enanthate for 3 months can be used [91]. 
This is particularly the case when children experience 
social anxiety or difficulties in urinating while standing, or 
if there are concerns regarding adequate penile length for 
penetrative sexual intercourse in adulthood [104].
Induction of male puberty in individuals with known 
DSD should be started from the age of 12 years through 
increasing dose of intramuscular, oral, or topical testos-
terone. Adverse effects of androgen pubertal induction 
include erythrocytosis, weight gain, and irreversible devel-
opment of male secondary sex characteristics, which may 
be distressing in case of GD. Intramuscular testosterone 
esters can be started at a dose of 50 mg monthly, increasing 
by 50-mg intervals every 6–12 months to a dose of 250 mg 
monthly, at which point a long-acting adult testosterone 
formulation can be commenced (testosterone undecanoate 
1000 mg every 12 weeks, [51, 91]). Otherwise, oral tes-
tosterone undecanoate 40 mg daily can be given with the 
evening meal and gradually titrated upward every 6 months 
to an adult dose of 160–240 mg per day, or to other tes-
tosterone formulations [51, 91]. Topical testosterone gel 
(available as 1 or 2 % testosterone strength) can be started 
with one-third of the daily adult dose for the first year and 
gradually increased by one-third daily every year to the 
adult daily dose by the third year [51].
In the case of patients with PAIS reared as males, in 
order to overcoming the androgen resistance, supra-physio-
logical doses of testosterone (up to five times of the typical 
dose for age) can be used to induce virilization, decrease 
gynecomastia, and improve body mass density [105]. Aro-
matase inhibitor can be added to prevent the development 
of gynecomastia.
High dose of testosterone has been used in the past 
also in 5-alpha-reductase deficiency to optimize available 
enzyme function. Alternative, topical treatment with 2.5 % 
of dihydrotestosterone gel has been reported to increase 
successfully virilization in affected persons [91].
DSD with female gender assignment and identity
In girls with DSD and absence of endogenous estrogen 
production (i.e., for gonadal digenesis or gonadectomy), 
pubertal induction can be started since the age of 11 years, 
using estrogens at gradually increasing doses [51, 91]. In a 
setting of short stature, it is preferred to start estrogen from 
12 years, to maximize the pubertal growth spurt. Natural 
estrogens, such as oral 17-beta-estradiol, are preferable to 
synthetic estrogens. Oral 17-beta-estradiol can be adminis-
tered with a starting dose of 0.25 mg per day, increasing 
the dose every 6 months to an adult dose of 2 mg per day 
[91, 106]. The initial dose of transdermal 17-beta-estradiol 
is 6.2 mcg per 24 h (one-quarter of a 25 mcg/24-h matrix 
patch), increasing gradually to an adult dose of 100 mcg 
per 24 h. In the presence of a uterus, when the adult dose 
of estrogen is attained (or earlier if menarche occurs), pro-
gesterone must be added (e.g., medroxyprogesterone ace-
tate 10 mg daily for the last 7 days of the menstrual cycle, 
[91]). In case of complete androgen insensitivity syndrome 
(CAIS) or PAIS, if gonadectomy is delayed after puberty, 
or event not performed, circulating oestradiol levels are 
enough to induce spontaneous development of female sec-
ondary sexual characteristics (including breasts, [105]). 
In the case of gonadectomy, supplementation of estrogens 
may be required in these patients in order to maintain 
serum oestradiol in the 300–400 pmol/l range [91, 105]. In 
patients who undergo gonadectomy before puberty, estro-
gens should be started at a low dose and up-titrated based 
on pubertal progression of bone age [105].
Specific clinical aspect according to different DSD 
diagnoses
46,XX DSD
Androgen excess in congenital adrenal hyperplasia 
(CAH) Of all 46,XX patients seen in clinical practice, CAH 
accounts for a vast majority. Inactivation or loss-of-function 
mutations in five genes critical to steroid biosynthesis are 
implicated in CAH (CYP21, CYP11B1, CYP17, HSD3B2, 
and StAR) [57, 107]. While all are characterized by impaired 
cortisol secretion, only CYP21 and CYP11B1 deficiencies 
are associated with a masculinizing disorder (and HSD3B2 
to a lesser extent) in 46,XX individuals [1]. In fact, as one 
of the several endocrine consequences, 46,XX fetuses with 
these enzymatic deficiencies are exposed to unusually high 
levels of androgens during fetal development, which vari-
ably masculinize the genitalia and presumably also the brain 
and later behavior [50, 108, 109]. Defective conversion of 
17-hydroxyprogesterone to 11-deoxycortisol (CYP21 defi-
ciency) accounts for more than 90 % of cases of CAH [110]. 
Psychosocial assessments have demonstrated that CAH 
women, when compared to controls, report more cross-gen-
der typical role behavior and patterns during childhood [25, 
63, 111, 112], with a preference for typically male toys [24, 
111–116] and playmates [25, 114]. Moreover, it has been 
reported that they are less interested in maternal rehearsal 
play, feminine makeup, and accessories [115, 117, 118]. 
Few were comfortable with their sense of femininity during 
childhood [119]. When gender-related behavior assessment 
in adult women with CAH was performed as a function of 
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disease severity, it was observed that women with the non-
classical or late-onset CAH showed few signs of gender 
shifts, the simple-virilizing women were intermediate, and 
the salt-wasting variants were the most severely affected 
[111]. Furthermore, a recent study has reported that gen-
der identity, measured as a continuous variable, may cor-
relate in 46,XX CAH with indicators of androgen exposure 
[120]. In addition, some studies reported a delay of sexual 
experiences, a reduced interest in sexual activities, lower 
maternalism, and a higher prevalence of bi- or homosexual 
orientation in women with CAH compared to the general 
female population [24, 25, 121–127]. Moreover, it has been 
observed that girls with CAH who show the greatest altera-
tions in childhood play behavior may be the most likely 
to develop a bisexual or homosexual orientation as adults 
[122] and that rates of bisexual and homosexual orienta-
tion were found to be correlated with the degree of prenatal 
androgenization [109] as well with genotype severity [128].
However, when GD was considered, only a few cases 
have been described, with some changes from female-to-
male gender, as reported by some authors [74, 123, 130–
132]. In fact, even if there is a strong evidence (40.9 %) of 
behaviors considered more typical of male gender identity 
[63], the majority (95 %) of 46,XX patients with CAH 
raised as females develop a female gender identity later 
on [24]. Although this rate far exceeds GD in the gen-
eral population, the absolute proportion is quite low [129, 
133], and it cannot be predicted from genital virilization 
[22, 23, 128, 134]. It could be concluded on the basis of 
these findings that, as female gender identity is the most 
common outcome despite markedly masculinized gender-
related behavior, patients diagnosed in the neonatal period, 
particularly with lower degrees of virilization (Prader 3 or 
less), should be raised as female [35, 95, 135]; those with 
delayed diagnosis may present more difficulties and may 
need to be evaluated carefully by a multidisciplinary team 
[61]. It should be considered in fact that cases of successful 
male assignment have been reported in 46,XX CAH indi-
viduals with late diagnosis and virilization resulting from 
hormonal imbalance [136, 137]. On this regard, Houk and 
Lee recently proposed consideration of male assignment 
for those with fully developed male genitalia when the par-
ent’s input is supportive [35]. In summary, a psychologi-
cal counselling focused on gender identity and GD in CAH 
children and adolescents and in their families is recom-
mended [95]. In addition, counselling should include also 
QoL issues, considering the poorer health-related QoL 
recently observed in these patients [95, 138, 139].
46,XY, DSD with typical female external genitalia at birth
Complete gonadal dysgenesia (Swyer syndrome) In 
46,XY complete gonadal dysgenesia, no testicular devel-
opment occurs and therefore patients present a complete 
lack of androgenization of the external genitalia and nor-
mal Müllerian structures, due to the absence of gonadal 
steroid and AMH production [95]. Some authors [140] 
suggest that subjects affected by Swyer syndrome, [5], 
have to be reared as female on the basis of following con-
siderations:
1. Typical female psychosexual development is reported 
in this syndrome [141].
2. Pregnancy can be successfully carried out with egg 
donation by affected individuals reared as female 
[141–146].
3. Reconstructive surgery is not required for the external 
genitalia to be consistent with the female gender.
4. Hormone replacement therapy is needed at puberty 
irrespective of the gender of rearing due to the high 
risk in these cases of developing germ-cell tumors 
from the dysgenetic gonads [141, 143, 147, 148].
CAIS In XY individuals with CAIS, the external genita-
lia appear to be completely female at birth. However, due 
to the effect of the AMH secreted by the testes, inducing a 
regression of the Mullerian ducts, the internal genitalia are 
lacking [149]. Classically, patients present in adolescence 
with primary amenorrhea and absence of post-pubertal 
pubic and axillary hair, but can also be discovered in infancy 
with inguinal or labial swelling containing testis [95, 105]. 
Although estimations of the risk of developing gonadal 
malignancies vary, overall the risk before puberty is low in 
CAIS patients [105, 150, 151]. In addition, no relationship 
exists between the timing of performing a gonadectomy and 
bone mineral density. On these bases, it has been suggested 
that gonadectomy in CAIS may safely be delayed until after 
puberty [105], monitoring retained testes for the develop-
ment of malignancy [152].
Regarding gender assignment, it has been suggested [95, 
140] that subjects with a CAIS should be reared as female 
because:
1. In accordance with the presumed absent androgeni-
zation of the brain, CAIS subjects have a well-docu-
mented female-typical core gender identity, gender role 
behavior and sexual orientation toward males, and they 
do not appear to suffer from GD [25, 67, 153–156]. 
These data were confirmed by Mazur which reported 
in a review of the literature, among 157 subjects with 
CAIS assigned and raised as females, no cases of gen-
der reassignment to male gender [149].
2. No surgery is needed for the external genitalia to be 
consistent with female gender [140].
3. Although hormone replacement treatment (with estro-
gens) is needed at the time of gonadectomy [105], 
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androgen resistance makes testosterone replacement 
untenable [147, 148].
However, two cases with some degree of GD have 
recently been reported [157, 158]. If in the first case the 
social and family pressures may have hypothetically con-
tributed to the male gender assignment request [157], this 
was not the case of the second [158]. The latter had a strong 
and persistent GD leading to a complete male gender reas-
signment involving mastectomy and phalloplastic proce-
dures [158]. According to the authors, the development of 
male gender identity in a phenotypic female patient, with a 
complete lack of a functioning androgen receptor, questions 
the role of the androgen receptor pathway in the develop-
ment of male gender identity [158]. However, based on the 
convincing literature, and with the report of only few cases 
with GD, rearing subjects with CAIS as a female sex must 
remains a standard procedure.
5‑alpha‑reductase‑2 deficiency Most newborns with 
5-alpha-reductase-2 deficiency (the enzyme converting tes-
tosterone into dihydrotestosterone) have female external 
genitalia at birth, although few infants may present with 
ambiguous genitalia. Testes are usually undescended, the 
Wolffian ducts are stabilized to form epididymides, vas def-
erens, seminal vesicles, and ejaculatory ducts, and there is a 
blind vaginal pouch [1]. Most affected infants are assigned 
a female sex and raised as girls. Profound virilization occurs 
at puberty in the form of deepening of the voice, substantial 
growth of the phallus, rugation, and hyperpigmentation of 
the scrotum, as well as increased muscle mass. A gender role 
change from female to male during adolescence and adult-
hood is reported in 56–63 % of subjects [77]. Several factors 
may determine whether these subjects (as well as those with 
17-beta-hydroxysteroid dehydrogenase type 3 deficiency, 
described below), raised as females, make a switch after 
puberty. A possible biological factor is represented by the 
severity of the deficiency in enzyme production, causing 
a variable exposition of the brain to androgens. However, 
the duration and extent of prenatal brain exposure to andro-
gens is difficult to determine retrospectively at birth or later, 
and, unfortunately, no data are available on the relationship 
between the developing of a male gender identity and cir-
culating androgens before, during, and after the gender role 
change. Moreover, cultural or other environmental pressures 
(such as family) have been mentioned has potential influ-
encing factors. Furthermore, the genital appearance (male, 
female, or ambiguous) may influence the self-body image 
and therefore the gender identity. In summary, it has been 
postulated that the pubertal changes which occur in these 
subjects’ bodies, in association with a masculine appearance 
in childhood and with masculine behavior (hypothetically 
caused by prenatal exposure to androgens), could reinforce 
an already existing gender discomfort [77]. On the basis of 
the reported high percentage of subjects requesting female-
to-male gender reassignment after puberty, together with 
fertility potential [77, 159], a male gender assignment is 
normally recommended in these 46,XY DSD, despite the 
female-appearing external genitalia. In addition, it should 
be considered that in this syndrome, genital tissue is respon-
sive to androgens, even if undermasculinized genitalia are 
unlikely to ever appear completely male-typical, despite 
medical and/or surgical treatment. Moreover, hormonal 
replacement is not necessary at puberty for subjects reared 
as male if the testes are not removed [140].
17‑beta‑HSD‑3 deficiency
17-beta-HSD-3 deficiency results in impaired testicu-
lar conversion of Delta4-Androstenedione into testoster-
one [160]. Affected subjects commonly present a female 
appearance of the external genitalia at birth. Hence, female 
gender is generally assigned, and subjects are reared 
accordingly [161]. In subjects reared as females, if diag-
nosis has not been established before puberty and gonads 
are nor removed surgically, virilization occurs at puberty 
with development of male body habitus, male muscle 
mass, abundant body hair and beard, and deepening of the 
voice; enlargement of cricoid cartilage may be present. The 
clitoris enlarges, but it remains undersized compared to a 
penis. Testicular volume also increases and may reach the 
range of normal adult males. Gynecomastia does not usu-
ally occur, but has been reported in some patients [161]. A 
recent literature review reported that female-to-male gender 
role change occurs frequently (39–64 %) but not invariably, 
usually in late adolescence or early adulthood [77, 159–
162]. As in 5-alpha-reductase deficiency, in 17-beta-HSD-3 
deficiency, there is not to date a clear relationship between 
the severity of the enzymatic defect and gender identity and 
why changes in gender role occur in some patients but not 
in others [77, 162–167]. Moreover, it has been suggested 
that unidentified pre- and postnatal factors, a better knowl-
edge of the natural history of the disorder in some areas, 
and sociocultural issues may participate, all together, 
in influencing gender identity and role [77, 161, 163]. 
In fact, biological factors aside, socialization and learn-
ing, have been shown to contribute significantly to gen-
der identity and role [168]. Up to now, data supporting a 
male gender assignment in these subjects are not as strong 
as for 5-alpha-reductase deficiency. Moreover, it should be 
taken into account that an intermediate risk for germ-cell 
tumors exists for 17-beta-HSD-3 deficiency, and there are 
no reports of fertility thus far [140]. In particular, regarding 
the latter, it is unknown whether early testosterone therapy 
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and orchidopexy would result in a more favorable outcome 
[168]. Consequently, female gender assignment may be 
appropriate in some situations; regular testicular evaluation 
is required for those reared male who have not had their 
testes removed [147].
46,XY DSD with ambiguous external genitalia at birth
PAIS Despite normal androgen production, presentation 
of external genitalia in PAIS is highly variable and can 
range from a penis with perineoscrotal hypospadias, with 
or without cryptorchidism, to a micropenis, with or with-
out hypoplasticlabioscrotal swellings, which may or may 
not be completely fused to form a scrotum [169]. Infants 
with PAIS are assigned to either the male or female gender, 
depending to some extent on the degree of hypomasculini-
zation. Virilization at puberty is also variably incomplete 
[149]. Gender identity shows considerably greater fluidity 
among persons born with PAIS [96, 170]. In fact, gender is 
not fully defined by genotype or external genitalia, but is a 
complex phenomenon, involving biological and social fac-
tors [105]. Therefore, surgical and medical treatment can 
assign phenotypic sex, but not gender identity [105]. For 
example, on the basis of the Mazur review of literature, 
among 99 subjects diagnosed with PAIS, nine (both male 
and female initial sex assignments) changed gender dur-
ing their lifetime [149]. In addition, GD without a com-
plete gender change was also reported [171]. Interestingly, 
gender change has not been shown to be correlated with 
a specific androgen receptor gene defect. As the evidence 
available up to now does not provide a clear guideline on 
gender assignment, it should be concluded that gender 
assignment in newborns with PAIS remains challenging, 
but gender identity is usually in line with the gender of 
rearing. When possible, choices regarding nonessential 
and irreversible interventions should be delayed until the 
patient is old enough to take part in the decision-making 
process [105].
Isolated micropenis
Studies on subjects with micropenis demonstrated an inar-
guable establishment of male role by all patients, as well 
as the establishment of a successful sexual relationship 
[104, 149, 172]. In fact, it should be taken into account that 
testosterone therapy in micropenis caused by fetal testos-
terone deficiency results in a functionally adequate penis, 
even if penile length usually remains significantly shorter 
than the reference values for young adults [104, 173–175]. 
Available data suggest that there is no clinical [104], physi-
ologic [176], or psychological [177, 178] basis for consid-
ering gender reversal in infants with micropenis and they 
should therefore be raised as males.
Cloacal exstrophy
46,XY subjects with cloacal exstrophy have been raised 
as female in the past, but recent studies suggest a variable 
outcome in terms of gender identity, as more than 60 % of 
subjects assigned female presented female-to-male gen-
der change [179, 180]. On this basis, recent attitudes have 
changed among clinicians more often favoring male gender 
assignment in these subjects [180, 181].
Isolated hypospadias
Several factors related to hypospadias could expose the 
subject to an increased risk of psychosexual maladjustment: 
the stress related to a praecox genital surgery, the possible 
poor aesthetic and functional results of surgery procedures, 
and finally the abnormal prenatal androgen exposure and/or 
androgen receptor defects to which they have been possibly 
subject. It has been observed that a more pronounced mas-
culine gender role behavior was predicted by a younger age 
at final surgery [182]. Vice versa, the number of surgeries 
has been found to be positively correlated with increased 
gender-atypical behavior [183].
Sex chromosome DSD
47,XXY Klinefelter syndrome and variants Men with 
Klinefelter syndrome, which is one of the most com-
mon forms of sex chromosome aneuploidy, usually report 
a male gender identity. However, a recent Belgian study 
described a significantly higher prevalence of Klinefelter 
syndrome among male-to-female GD [184] than expected, 
based on the population data [185]. In addition, a recent 
study showed the presence of higher dysphoric symptoms 
in Klinefelter persons compared to a group of healthy con-
trols [186]. However, levels of GD observed were not at 
critical threshold to suggest a GD diagnosis and should be 
better considered in light of the dimensional construct of 
GD. Moreover, moderator analyses showed that gender dys-
phoric symptoms observed in Klinefelter population might 
be an epiphenomenon of the autistic traits [187].
However, it should be recognized that GD in Klinefelter 
syndrome has not been systematically studied in large sam-
ples, and it is possible that not all karyotype variations have 
been reported by other gender teams, specifically in rela-
tion to the finding of Klinefelter syndrome [184].
Mixed gonadal dysgenesis In individuals with mixed 
gonadal dysgenesis, marked differences in gonadal devel-
opment and histology can be seen between the right and the 
left sides or even within a single gonad. Genital phenotypes 
could range from normal female external genitalia or mild 
clitoromegaly through all stages of ambiguous genitalia, to 
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hypospadias or to normal penis. Prenatal androgen expo-
sure, internal ductal anatomy, gonadal function and, after 
puberty, phallic development, and gonadal location have to 
be considered when sex rearing must be decided [187].
Ovotesticular DSD Also known as “true hermaphrodit-
ism,” ovotesticular DSD is characterized by the presence 
of both ovarian and testicular tissues in either the same or 
opposite gonad and by genital ducts which usually differen-
tiate following the homolateral gonad. Most patients have 
ambiguous genitalia at birth or significant hypospadias. At 
the time of puberty, breast development, menses, and pro-
gressive androgenization could occur depending on the sig-
nificance of ovarian and testicular tissue. The management 
varies on the basis of the age of diagnosis and anatomical 
differentiation. Either male or female assignment may be 
appropriate when the diagnosis is made at a young age and 
gender identity has not yet become defined. The decision 
on sex of rearing in ovotesticular DSD should consider the 
potential for fertility based on gonadal differentiation and 
genital development and assuming the genitalia are, or can 
be made, consistent with the chosen sex [107, 187].
Summary
The suggested strategy for gender assignment of a new-
born with genital ambiguity should not be based only on 
the appearance of the genitalia at birth, as the degree of 
genitalia virilization does not necessary correlate with the 
degree of brain masculinization. In fact, there are tempo-
ral trends in gender assignment that are independent of 
this external appearance. The results from a recent analy-
sis in Europe (I-DSD registry) [188] clearly reveal that the 
practice of assigning female sex in newborns with 46,XY 
DSD seems to be decreasing. The change in practice 
was not due to a higher degree of masculinization of the 
cases raised as boys. This practice could have been influ-
enced by reports on adequate long-term outcome in men 
with 46,XY DSD and conditions such as micropenis and 
an improved surgical outcome of penile reconstruction or 
neophallus construction [174]. It is likely that this prac-
tice has also been influenced by those cases of XY DSD 
who were raised as girls and who developed GD, although 
other similar cases in which GD was not encountered have 
received less attention [179]. In summary, the multidiscipli-
nary DSD team needs to carefully weigh and balance the 
genital appearance, the clinical options (also in terms of 
fertility), the cultural pressures as well as the parental view 
and support [95]. Moreover, when a specific diagnosis can 
be made, recommendations for gender assignment can be 
based upon outcome data, when available for the specific 
DSD diagnosed. Regular psychological support and gender 
counselling should be available to the child and the fam-
ily as part of a multidisciplinary service to DSD in order to 
ensure psychological and social well-being throughout dif-
ferent developmental stages. Furthermore, a psychological 
evaluation is recommended in case of distress or discom-
fort related to gender-atypical behaviors experienced by the 
child or by his/her family. In particular, this should be per-
formed by a MHP skilled in GD in children and adolescents 
to assess the child’s gender identity, the presence of GD, 
and psychosocial functioning. In case of GD in DSD condi-
tions where no clear gender identity outcome can be pre-
dicted, the prescription of GnRHa, following the WPATH 
and the Endocrine Society guidelines [88, 89], should also 
be considered. Such option could allow the child and fam-
ily to gain time to clarify gender issues and reassignment 
decision making. Also, in the case of a gender assignment 
at birth different from the recommended one, an early psy-
chological evaluation performed by a MHP as well as the 
prescription of GnRHa should be considered, in some cases 
also before puberty onset. A complete social transition to 
the opposite gender is recommended in case of strong and 
persistent GD and desire to live fully in the opposite gender 
role and/or in case of an early onset of cross-gender behav-
iors [88].
In conclusion, it should be taken into account that every 
DSD subject is unique and has to be treated with individu-
alized care. Researches for further understanding of spe-
cific outcomes are needed. In this perspective, international 
registries (e.g., I-DSD Registry, DSD-Life, DSD-net, and 
DSD-TRN, [96]) are crucial to improve the understand-
ing of these challenging conditions and clinical practice, in 
providing a better prediction of gender identity and com-
mon clinical procedures [96, 188–190].
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